Axovant shares plummet 74% on failure of Alzheimer’s disease trial
September 26, 2017 at 09:53 AM EDT
Many companies are working to develop an Alzheimer’s disease treatment, but it has been a difficult path.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.